Metabo-oncology — which focuses on the link between cancer and metabolic dysfunction — is poised to spark a paradigm shift in cancer treatment. SynDevRx is the leader in this emerging field. Their lead compound, SDX-7320 is a methionine aminopeptidase type II (MetAP2) inhibitor that proposes to both treat the tumor directly and correct the underlying metabolic dysfunction — sort of a one-two punch to cancer.